Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
Nov 21 AZN AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
Nov 21 APLS Apellis started at equal-weight at Morgan Stanley on geographic atrophy market
Nov 21 AZN We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
Nov 21 AZN 3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
Nov 21 AZN AstraZeneca upgraded to Neutral from Sell at UBS
Nov 21 AZN AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg
Nov 20 AZN AstraZeneca raised to neutral at UBS despite China headwinds
Nov 20 AZN AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
Nov 20 AZN Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Nov 20 AZN AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
Nov 20 AZN FTSE 100 and European-listed stocks to own in 2025, according to Barclays
Nov 19 DVAX Dynavax Technologies Corporation (DVAX): This Small-Cap Stock Is Ready To Explode
Nov 19 AZN CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
Nov 19 AZN AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
Nov 19 AZN CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
Nov 18 AZN GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Nov 18 AZN AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership
Nov 18 AZN Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Nov 18 AZN Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now?
Nov 18 APGE Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags